Beryl Drugs
Beryl Drugs Share Price Chart
Beryl Drugs last traded at ₹25.49 (2026-10-13). Over the past month the stock moved +5.7%, three months the stock moved +33.9%, year the stock moved +11.6%. Its closing range over 52 weeks is ₹18.40 – ₹26.40, with the latest close 3.4% below the high.
Closing prices up to 2026-10-13.
About Beryl Drugs
Incorporated in 1993, Beryl Drugs Ltd is in the business of pharmaceuticals manufacturing[1]
Business Overview:[1] BDL is mainly engaged in the domestic, institutions, and export supply of bulk drugs, pharmaceuticals, and healthcare products like I.V. Fluids and Small Volume Injectables. It manufactures and markets a range of branded, generic pharmaceutical formulations through its nationwide sales and distribution network and provides research and development, contract manufacturing services, and veterinary products.
Fundamentals
Quarterly Results
In the latest quarter (Jun 2026), Beryl Drugs reported sales of ₹7.57 crore (+56.7%) and net profit of ₹0.22 crore (+1000.0%), compared with the same quarter last year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Jun 2026 | 7.57 | 0.65 | 8.59 | 0.22 | 0.43 |
| Mar 2026 | 5.47 | 1.34 | 24.50 | 0.56 | 1.10 |
| Dec 2025 | 3.85 | -0.20 | -5.19 | -0.17 | -0.34 |
| Sep 2025 | 5.16 | 0.73 | 14.15 | 0.01 | 0.02 |
| Jun 2025 | 4.83 | 0.55 | 11.39 | 0.02 | 0.04 |
| Mar 2025 | 5.22 | 0.50 | 9.58 | 0.15 | 0.30 |
| Dec 2024 | 5.40 | 0.59 | 10.93 | 0.05 | 0.10 |
| Sep 2024 | 5.64 | 0.56 | 9.93 | 0.01 | 0.02 |
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | -30.3% | -29.5% | +62.6% | -23.2% | -8.5% | -28.7% | +4.8% | +56.7% |
| Operating profit growth | -22.2% | -25.3% | +2400.0% | -44.4% | +30.4% | -133.9% | +168.0% | +18.2% |
| Net profit growth | -96.3% | -83.9% | – | -94.6% | +0.0% | -440.0% | +273.3% | +1000.0% |
| EPS growth | -96.2% | -83.6% | – | -94.5% | +0.0% | -440.0% | +266.7% | +975.0% |
| OPM % | 9.9% | 10.9% | 9.6% | 11.4% | 14.2% | -5.2% | 24.5% | 8.6% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Annual Financials
In the latest year (Mar 2026), Beryl Drugs reported sales of ₹19.31 crore (-14.4%) and net profit of ₹0.42 crore (-27.6%), compared with the previous year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Mar 2026 | 19.31 | 2.42 | 12.53 | 0.42 | 0.83 |
| Mar 2025 | 22.56 | 2.64 | 11.70 | 0.58 | 1.14 |
| Mar 2024 | 26.72 | 2.36 | 8.83 | 0.77 | 1.52 |
| Mar 2023 | 26.84 | 2.00 | 7.45 | 0.77 | 1.52 |
| Mar 2022 | 14.48 | 0.44 | 3.04 | -0.66 | -1.30 |
| Mar 2021 | 14.03 | 1.45 | 10.33 | 0.24 | 0.47 |
| Mar 2020 | 12.78 | 0.91 | 7.12 | 0.05 | 0.10 |
| Mar 2019 | 12.81 | 1.03 | 8.04 | 0.59 | 1.16 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | -15.1% | -0.2% | +9.8% | +3.2% | +85.4% | -0.4% | -15.6% | -14.4% |
| Operating profit growth | -1.0% | -11.7% | +59.3% | -69.7% | +354.5% | +18.0% | +11.9% | -8.3% |
| Net profit growth | -40.4% | -91.5% | +380.0% | -375.0% | – | +0.0% | -24.7% | -27.6% |
| EPS growth | -40.5% | -91.4% | +370.0% | -376.6% | – | +0.0% | -25.0% | -27.2% |
| OPM % | 8.0% | 7.1% | 10.3% | 3.0% | 7.5% | 8.8% | 11.7% | 12.5% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Shareholding
AI Analysis
No AI analysis generated yet for Beryl Drugs.
Get Free AI Stock Analysis FREE →Latest News
-
Beryl Drugs standalone net profit rises 1000.00% in the June 2026 quarter - Business Standard
-
Beryl Drugs Limited Concludes Extra-Ordinary General Meeting on May 11, 2026; Approves Director Appointments and Related Party Transactions - scanx.trade
-
Beryl Drugs Limited Concludes Extra-Ordinary General Meeting on May 11, 2026; Approves Director Appointments and Related Party Transactions - scanx.trade
Frequently Asked Questions
What is the share price of Beryl Drugs today?
Beryl Drugs shares were last quoted at ₹25.49 (-3.1% on the day). Use the Refresh price button on this page for the latest available price. Prices are for information only.
What is the P/E ratio of Beryl Drugs?
Beryl Drugs has a price-to-earnings (P/E) ratio of 7.79 and a price-to-book (P/B) ratio of 2.00. The industry P/E is 52.82.
What is the 52-week high and low of Beryl Drugs?
The 52-week high of Beryl Drugs is ₹27.60 and the 52-week low is ₹15.92.
What is the market cap of Beryl Drugs?
The market capitalisation of Beryl Drugs is about ₹12.13 crore.
How did Beryl Drugs perform in its latest quarterly results?
In the latest quarter (Jun 2026), Beryl Drugs reported sales of ₹7.57 crore (+56.7%) and net profit of ₹0.22 crore (+1000.0%), compared with the same quarter last year.
Is Beryl Drugs a good stock to buy?
This page is for information and is not investment advice. As per the data shown here, Beryl Drugs has a 3-year ROE of 6.00%, 3-year profit growth of -18.00%. Review the fundamentals, quarterly results and AI analysis on StockSpin, and consult a SEBI-registered adviser before investing.
What is the promoter holding in Beryl Drugs?
Promoters hold about 27.82% of Beryl Drugs.
Which sector does Beryl Drugs belong to?
Beryl Drugs belongs to the Pharmaceuticals & Drugs sector.